Regulation Tracker.
Dated changes to advertising regulation across the markets we work in — KKM/MOH, MDC, AHPRA/TGA, PDPA/PDPC and platform ad policy.
shakalakaa's regulation tracker logs dated advertising-regulation changes in Malaysia, Singapore and Australia for clinic groups, healthcare brands and other regulated advertisers. It covers KKM/MOH, MDC, AHPRA/TGA and PDPA/PDPC, launched on 2026-07-30 with exactly 3 sourced entries, and adds one only when a real, dated change is found.
Tracked changes
Each entry: what changed, what it means for advertisers, and a real source.
| Date | Market | Regulator | What changed | Impact | Source |
|---|---|---|---|---|---|
| 2025-09-02 | AU | AHPRA / Medical Board of Australia | AHPRA's cosmetic procedure advertising guidelines took effect, strengthening the existing National Law s133 testimonial ban to explicitly cover influencer content and re-shared patient stories, banning appearance-prediction tools/apps, prohibiting advertising cosmetic procedures to under-18s outright, and introducing a mandatory 7-day cooling-off period for under-18 patients where a procedure is clinically appropriate at all. | What it means for advertisers: Testimonials, before/after-adjacent tools, and under-18-targeted cosmetic ads are all now explicitly out of scope for Australian cosmetic clinic advertising — compliant creative needs to convert on practitioner credibility, process transparency and education instead. | Source (opens in a new tab) |
| 2022-10-01 | SG | PDPC (Personal Data Protection Commission), Singapore | PDPA section 48J financial penalty amendment took effect, materially raising the penalty regime for Do Not Call Registry and data-protection breaches. | What it means for advertisers: WhatsApp/SMS lead follow-up campaigns in Singapore carry meaningfully higher financial exposure for DNC violations than before this date — verifying opt-out handling and DNC registry checks is a materially higher-stakes compliance item post-amendment. | Source (opens in a new tab) |
| 2022 | SG | MOH (Ministry of Health), Singapore | MOH Direction 02/2022 (Annex 1) — guidance for PHMCA/HCSA licensees on advertising, including restrictions on laudatory/superlative terms (§5.3(c)) and prescription-medicine naming (§4.2, Appendix A). | What it means for advertisers: Singapore clinic ad copy naming prescription products or using superlative/laudatory language ('best,' 'leading,' etc.) falls under this direction's restrictions — exact day-level date not independently confirmed beyond the document's own '02-2022' designation, stated honestly rather than guessed. | Source (opens in a new tab) |
How entries are added
Regulation tracker, in depth
The supporting detail behind each section of this page, by topic. 1 topics
Citing this page
- Cite this
- shakalakaa (Plixitt Solutions). “Regulation Tracker.”
- https://shakalakaa.my/resources/regulation-tracker · Updated 2026-10-16
- Licensed under CC BY 4.0.
Keep exploring
Frequently asked
What does this regulation tracker cover?
Dated changes to advertising regulation across the markets we work in — KKM/MOH and MDC in Malaysia, AHPRA/TGA in Australia, PDPA/PDPC in Singapore, and platform ad policy. Each entry records what changed, what it means for advertisers, and a real source.
How many entries does it have, and why so few?
It launched on 2026-07-30 with exactly 3 sourced entries, and it is not padded to look fuller. Each of those already had a real, dated, sourced citation elsewhere in our compliance content, so the tracker aggregates verified changes rather than manufacturing them.
How often is a new entry added?
Only when a real, dated regulatory change is found — never on a fixed schedule. A tracker that must produce an entry every month starts inventing significance, which would make it useless for the one job it has.
Is the tracker available as a feed or an API?
Yes — RSS and JSON are both available, so the tracker can be monitored programmatically rather than checked by hand.